> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ways to Increase Clinical Trial Diversity: PhRMA
- URL: https://www.fdaweb.com/ways-to-increase-clinical-trial-diversity-phrma/
- Published: 2023-03-22T12:00:00.000Z
- Updated: 2026-09-14T18:21:25.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154043

In comments to the White House Office of Science and Technology Policy (OSTP), Pharmaceutical Research and Manufacturers of America (PhRMA) presents three ways to increase diversity in clinical trials. PhRMA [says](https://catalyst.phrma.org/phrma-shares-ostps-recognition-of-the-importance-of-having-a-clinical-trial-infrastructure-that-supports-sites-that-are-ready-to-respond-to-emergency?ref=fdaweb.com) OSTP solicited stakeholder feedback on the clinical research infrastructure for emergency clinical trials.

The trade association says it shares OSTP’s recognition of the importance of having a clinical trial infrastructure that supports sites that are ready to respond to emergencies like Covid-19\. “We also agree that one goal of such an infrastructure should be to support the expansion of clinical research into underserved communities by increasing diversity among both trial participants and clinical trial investigators,” it says.

The PhRMA comments present its views on:

- expanding clinical research sites in underserved areas;
- using decentralized clinical trials and digital health technology innovations; and
- having a network of sites in a state of readiness to undertake additional or future clinical research.